- ►endojournals.org MC Carr, JD Brunzell - Journal of Clinical Endocrinology & Metabolism, 2004 - Endocrine Soc Regional body fat distribution has an important influence on metabolic and
cardiovascular risk factors. Increased abdominal (visceral) fat accumulation is
a risk factor for coronary artery disease (CAD), dyslipidemia, ... Cited by 183 - Related articles - BL Direct - All 6 versions
R McPherson, J Frohlich, G Fodor, J Genest - The Canadian journal of cardiology, 2006 - pubmedcentral.nih.gov Since the last publication of the recommendations for the management and
treatment of dyslipidemia, new clinical trial data have emerged that support a
more vigorous approach to lipid lowering in specific patient groups. The ... Cited by 77 - Related articles - BL Direct - All 14 versions
CD Meyers, VS Kamanna, ML Kashyap - Current opinion in lipidology, 2004 - journals.lww.com Purpose of review Well designed, randomized, placebo-controlled studies show
that niacin prevents cardiovascular disease and death. Unfortunately, early
studies and anecdotal evidence have limited its use by promoting the ... Cited by 64 - Related articles - All 3 versions
PO Szapary, DJ Rader - American Heart Journal, 2004 - Elsevier Coronary heart disease is the single largest cause of morbidity and mortality in
the United States. The link between elevated low-density lipoprotein cholesterol
(LDL-C) levels and coronary heart disease (CHD) has been clearly ... Cited by 54 - Related articles - All 11 versions
JR Guyton, HE Bays - The American Journal of Cardiology, 2007 - Elsevier Niacin has beneficial effects on plasma lipoproteins and has demonstrated
clinical benefits in reducing cardiovascular events and atherosclerosis
progression. The side effects of niacin, however, have limited its use in ... Cited by 47 - Related articles - All 15 versions
JR Guyton - eop, 2004 - informahealthcare.com Niacin (nicotinic acid) favourably modifies all aspects of the lipoprotein pro-
file; it raises high-density lipoprotein cholesterol (HDL-C) levels, lowers
trig- lyceride, low-density lipoprotein cholesterol (LDL-C) and ... Cited by 36 - Related articles - All 4 versions
JR Guyton - Current opinion in lipidology, 2007 - journals.lww.com Purpose of review This review describes niacin's mechanism of action, efficacy
in cardiovascular prevention, and safety. Recent findings A G-protein-coupled
receptor [GPR109A/HM74A, mouse PUMA-G (protein upregulated in macrophages ... Cited by 25 - Related articles - BL Direct - All 5 versions
CD Meyers, P Liu, VS Kamanna, ML Kashyap - Atherosclerosis, 2007 - Elsevier Nicotinic acid is a safe, broad-spectrum lipid agent shown to prevent
cardiovascular disease, yet its widespread use is limited by the prostaglandin D
2 (PGD 2 ) mediated niacin flush. Previous research suggests that nicotinic ... Cited by 16 - Related articles - All 15 versions
CD Meyers, ML Kashyap - Endocrinology and metabolism clinics of North America, 2004 - Elsevier Characterized by insulin resistance, hypertension, abdominal obesity, and
specific lipid abnormalities, the metabolic syndrome is emerging as a major
cause of cardiovascular disease (CVD) and death in the Western world. ... Cited by 15 - Related articles - BL Direct - All 3 versions
EA Enas, V Chacko, A Senthilkumar, N … - Disease-a-Month, 2006 - Elsevier Lp(a) is a genetic variant of low-density lipoprotein (LDL) in which
apolipoprotein B100 is linked by a disulfide bond to apolipoprotein(a) [apo(a)].
17 and 18 Apo(a) is structurally similar to plasminogen and renders Lp(a) ... Cited by 15 - Related articles - All 2 versions
